SCHEDULE 13G/A: Investment Group Led by David Kanen Discloses 10.3% Stake in Aytu BioPharma

An investment group comprising Philotimo Fund, LP, Philotimo Focused Growth & Income Fund, Kanen Wealth Management LLC, and David L. Kanen has disclosed a collective beneficial ownership of 10.3% in Aytu BioPharma, Inc. common stock.

Summary

• Philotimo Fund, LP beneficially owns 425,500 shares of Aytu BioPharma, Inc. common stock, representing approximately 6.9% of the outstanding shares.
• Philotimo Focused Growth & Income Fund beneficially owns 209,573 shares, representing approximately 3.4% of the outstanding shares.
• Kanen Wealth Management LLC and David L. Kanen each beneficially own 635,073 shares, which constitutes approximately 10.3% of the outstanding shares.
• Kanen Wealth Management LLC is the general partner of Philotimo Fund, LP and the investment manager of Philotimo Focused Growth & Income Fund.
• David L. Kanen serves as the managing member of Kanen Wealth Management LLC.
• The aggregate beneficial ownership of the group, including Philotimo Fund, LP, Philotimo Focused Growth & Income Fund, Kanen Wealth Management LLC, and David L. Kanen, totals 635,073 shares.
• The percentage of class is based on 6,170,246 shares outstanding as of May 1, 2025, as reported in Aytu BioPharma's Quarterly Report on Form 10-Q filed on May 14, 2025.
• The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing pertains to Aytu BioPharma, Inc., a company operating in the biopharmaceutical industry. The disclosure of a significant beneficial ownership stake by an investment group is a common occurrence in the public markets, indicating an investor's position in a company's equity.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by an investment group can influence market perception and potentially signal investor confidence or strategic interest in the company.

Next Steps

• The reporting persons will continue to monitor their investment in Aytu BioPharma, Inc. and may file further amendments to Schedule 13G or Schedule 13D if their beneficial ownership changes significantly or if their investment intent shifts.

Key Dates

Keywords

Aytu BioPharma, AYTU, Schedule 13G, beneficial ownership, Philotimo Fund, Kanen Wealth Management, David L. Kanen, investment group, common stock, SEC filing, biopharma